Titiyal Jeewan S, Basak Samar K, Shetty Naren, Mathur Umang, Padmanabhan Prema, Ganesh Sri, Dey Arindam, Ramamurthy Dandapani
Department of Cornea and Refractive Surgery, All India Institute of Medical Sciences, New Delhi, India.
Department of Cornea and Cataract Services, Disha Eye Hospitals, Kolkata, India.
Clin Ophthalmol. 2022 Dec 16;16:4215-4225. doi: 10.2147/OPTH.S379054. eCollection 2022.
To assess real-world clinical outcomes and safety of the Clareon intraocular lens (IOL) and AutonoMe automated preloaded delivery system in an Indian population.
This was a prospective, single-arm, multicenter, 12-month clinical study in patients aged ≥20 years with unilateral or bilateral cataracts. Surgery was performed by phacoemulsification followed by implantation of the Clareon monofocal IOL (CNA0T0). Monocular best-corrected distance visual acuity (BCDVA) and uncorrected distance visual acuity (UCDVA) were assessed at 1 week and 1, 6, and 12 months after implantation. Posterior capsular opacification (PCO), surface haze, and glistenings were evaluated at all visits. Surgeons' satisfaction with automated injector system was also evaluated using a questionnaire. Safety was assessed by monitoring adverse events (AEs).
A total of 151 eyes received the CNA0T0 IOL. Mean ± SD monocular BCDVA improved from 0.53±0.44 logMAR preoperatively to 0.00±0.08 logMAR at week 1 and -0.03±0.08 logMAR at 12 months after implantation. At 12 months, 137/137 (100%) of eyes achieved BCDVA of 0.3 logMAR or better. Mean ± SD monocular UCDVA was 0.78±0.40 logMAR preoperatively, 0.11±0.15 logMAR at week 1, and 0.08±0.13 logMAR at 12 months after implantation. At 12 months, 132/137 (96%) eyes achieved UCDVA of 0.3 logMAR or better. Serious intraoperative AEs were posterior capsule rupture (n=1) and ciliary zonular dehiscence (n=1). Surgeons reported that the automated preloaded device was more intuitive compared with other push- or screw-style preloaded injector systems. None of the eyes in this study presented surface haze; all were graded as 0 glistenings at all visits. No clinically significant PCO or neodymium-doped yttrium aluminum garnet (Nd:YAG) capsulotomies were reported.
The hydrophobic IOL preloaded in an automated injector system provided good visual and refractive outcomes, as well as no surface haze and grade 0 glistenings. None of the patients required Nd:YAG capsulotomy.
评估Clareon人工晶状体(IOL)和AutonoMe自动预装式输送系统在印度人群中的真实世界临床疗效和安全性。
这是一项前瞻性、单臂、多中心、为期12个月的临床研究,研究对象为年龄≥20岁的单侧或双侧白内障患者。手术采用超声乳化术,随后植入Clareon单焦点IOL(CNA0T0)。在植入后1周、1个月、6个月和12个月评估单眼最佳矫正远视力(BCDVA)和未矫正远视力(UCDVA)。在每次随访时评估后囊膜混浊(PCO)、表面混浊和闪辉情况。还通过问卷评估外科医生对自动注射器系统的满意度。通过监测不良事件(AE)评估安全性。
共有151只眼植入了CNA0T0 IOL。单眼平均±标准差BCDVA从术前的0.53±0.44 logMAR提高到植入后1周时的0.00±0.08 logMAR以及12个月时的-0.03±0.08 logMAR。在12个月时,137/137(100%)的眼BCDVA达到0.3 logMAR或更好。单眼平均±标准差UCDVA术前为0.78±0.40 logMAR,植入后1周时为0.11±0.15 logMAR,12个月时为0.08±0.13 logMAR。在12个月时,132/137(96%)的眼UCDVA达到0.3 logMAR或更好。严重术中不良事件为后囊膜破裂(n = 1)和睫状小带断裂(n = 1)。外科医生报告称,与其他推注式或螺旋式预装注射器系统相比,自动预装设备更直观。本研究中所有眼均未出现表面混浊;在每次随访时所有眼的闪辉均分级为0级。未报告有临床意义的PCO或钕掺杂钇铝石榴石(Nd:YAG)后囊切开术。
预装在自动注射器系统中的疏水IOL提供了良好的视觉和屈光效果,且无表面混浊和0级闪辉。没有患者需要进行Nd:YAG后囊切开术。